Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/refractory Multiple Myeloma

Overview

Journal Blood Cancer J

Date 2025 Mar 4

PMID 40038247

Authors

James A Davis

Jordan Snyder

Mikhaila Rice

Donald C Moore

Christopher Cahoon

Kelley Julian

Charlotte B Wagner

Katelynn Granger

Kimberly M Green

Shebli Atrash

Hailey Hill

Jessica McElwee

Grace Elsey

Jack Khouri

Joslyn Rudoni

Zahra Mahmoudjafari

Victoria R Nachar

Affiliations

Soon will be listed here.

References

Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A . Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024; 38(2):365-371. PMC: 10844072. DOI: 10.1038/s41375-024-02154-5. View

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

Martin T, Mateos M, Nooka A, Banerjee A, Kobos R, Pei L . Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer. 2023; 129(13):2035-2046. DOI: 10.1002/cncr.34756. View

Rooney C, Sauer T . Modeling cytokine release syndrome. Nat Med. 2018; 24(6):705-706. DOI: 10.1038/s41591-018-0068-9. View

Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V . Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024; 14(1):35. PMC: 10914756. DOI: 10.1038/s41408-024-01003-z. View

Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R . Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination. J Adv Pract Oncol. 2025; 1-16. PMC: 11715450. DOI: 10.6004/jadpro.2024.15.8.15. View

Rodriguez-Otero P, Usmani S, Cohen A, van de Donk N, Leleu X, Gallego Perez-Larraya J . International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024; 25(5):e205-e216. DOI: 10.1016/S1470-2045(24)00043-3. View

Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V . Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer J. 2023; 13(1):191. PMC: 10730907. DOI: 10.1038/s41408-023-00963-y. View

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. View

10.

Costa B, Flynn J, Nishimura N, Devlin S, Farzana T, Rajeeve S . Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024; 14(1):84. PMC: 11130279. DOI: 10.1038/s41408-024-01048-0. View

11.

Dima D, Davis J, Ahmed N, Jia X, Sannareddy A, Shaikh H . Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Transplant Cell Ther. 2023; 30(3):308.e1-308.e13. DOI: 10.1016/j.jtct.2023.12.016. View

12.

Crombie J, Graff T, Falchi L, Karimi Y, Bannerji R, Nastoupil L . Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024; 143(16):1565-1575. DOI: 10.1182/blood.2023022432. View

13.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

14.

Kauer J, Horner S, Osburg L, Muller S, Marklin M, Heitmann J . Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020; 8(1). PMC: 7264835. DOI: 10.1136/jitc-2020-000621. View